BR5402B-1

BR5402B-1 is an investigational drug product containing olanzapine, developed by Boryung Pharmaceutical for the treatment of schizophrenia. It is currently being evaluated in a Phase 2 clinical trial (NCT06821945) designed to compare the safety and efficacy of different olanzapine titration schedules, specifically evaluating gradual versus conventional dosing regimens. Olanzapine, the active ingredient, is an atypical antipsychotic that functions as a multi-receptor antagonist, with high affinity for serotonin 5-HT2A and dopamine D2 receptors, as well as muscarinic, histamine, and adrenergic receptors. By modulating these neurotransmitter systems, it addresses the positive and negative symptoms of schizophrenia.